financetom
Business
financetom
/
Business
/
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Mar 11, 2026 9:16 AM

March 11 (Reuters) - Regenxbio ( RGNX ) said on

Wednesday that an interim data from a early-to-mid stage study

of its experimental gene therapy in patients with Duchenne

muscular dystrophy showed continued improvement in muscle

function and a clean safety profile.

(Reporting by Kamal Choudhury in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved